Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery

Yonsei University100 enrolled

Overview

This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

DOUBLE

Enrollment

100

Conditions

Non-thyroidal Illness Syndrome

Interventions

liothyronine sodiumDRUG

liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)

placeboDRUG

vitamin B12

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are undergoing Off-pump coronary artery bypass graft Exclusion Criteria: * No normal sinus rhythm, * History of thyroid disease * Abnormal thyroid hormone * Renal dysfunction * Hepatic dysfunction * LVEF \<30% * Recent MI * Active infection 1\~15

Locations (1)

Severance Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

compare the serum T3 concentrations and the number of patients with serum T3 concentrations below the normal range between the groups

Time frame: until 36 hours after surgery

Secondary Outcomes

difference of hemodynamic performance and myocardial injury

difference of hemodynamic performance and myocardial injury between the groups

Time frame: during surgery and 36 hr after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.